Search
Urogen Pharma Ltd
URGNAdd to Watchlist
38.240USD
-2.850-6.94%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.86BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Urogen Pharma Ltd is 8.75, ranking 61 out of 385 in the Biotechnology & Medical Research industry. The average price target is 34.00, with a high of 55.00 and a low of 16.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
41.125
Target Price
+7.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Urogen Pharma Ltd
URGN
8
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Urogen Pharma Ltd's expected revenue for the next quarter?
Urogen Pharma Ltd's expected revenue is 63.53M.
What is Urogen Pharma Ltd's price target?
Analysts forecast that Urogen Pharma Ltd's price target is USD 34.00, with the highest forecast at USD 55.00 and the lowest forecast at USD 16.00.
How have Urogen Pharma LtdURGN's recent earnings per share performed?
The market expectation was USD -0.47, while Urogen Pharma LtdURGN's earnings per share (EPS) for the previous quarter was USD -0.54. EPS for the next quarter is expected at USD -0.29.
What is the analyst rating for Urogen Pharma Ltd?
Based on the ratings of Urogen Pharma Ltd's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.